The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.20
Bid: 13.10
Ask: 13.30
Change: 0.00 (0.00%)
Spread: 0.20 (1.527%)
Open: 13.25
High: 13.40
Low: 13.20
Prev. Close: 13.20
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

Tue, 04th Oct 2022 08:46

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

The FTSE 100 index opened up 73.28 points, 1.1%, at 6,982.04. The FTSE 250 opened up 274.82 points, 1.6%, at 17,558.98 and the AIM All-Share opened up 6.51 points, 0.8% at 815.24.

The Cboe UK 100 opened up 1.3%% at 699.00, the Cboe UK 250 opened up 1.2% at 14,965.48, and the Cboe Small Companies opened 0.1% higher at 12,758.68.

In European equities on Tuesday, the CAC 40 in Paris opened up 2.2%, while the DAX 40 in Frankfurt opened up 2.0%.

Liz Truss has stressed she must take a "responsible" approach to the public finances, as she faces a Cabinet split and a fresh battle with Tory rebels fighting real-terms cuts to benefits.

The prime minister is refusing to rule out a return to austerity or say whether welfare payments will be increased in line with soaring inflation.

Critics who forced a U-turn over the plan to abolish the 45 pence tax rate for top earners are now stepping up pressure on the government to confirm benefits will be raised.

Meanwhile, the Conservative Party Conference continues in Birmingham.

Keynote speeches by Home Secretary Suella Braverman and Foreign Secretary James Cleverly will aim to set out the government's plans on immigration and commitment to support Ukraine.

As discontent brews within the party, Priti Patel is set to accuse Truss and Kwarteng of "spending today with no thought of tomorrow".

"I want to see our party regain its credibility by restoring its commitment to sustainable public spending...which is affordable today, tomorrow and for the foreseeable future," the former home secretary will tell a conference fringe event, according to The Times.

"The UK government's decision to reverse part of its previous tax-cutting plan also had a disproportionately positive effect on sentiment generally, with sterling recouping some of its previously precipitous losses following the initial announcement," interactive investor's Head of Markets Richard Hunter said.

The pound was quoted at USD1.1365 at the London equities open Tuesday, continuing to rise from USD1.1309 at the close on Monday.

Hunter added: "Nonetheless, the longer term impact of the attempt to stimulate growth is yet to be proven, while the government's initial announcement seemed at odds with what the Bank of England is trying to achieve."

In the FTSE 100, Legal & General added 4.7% in early trading.

The financial services firm said it has maintained positive momentum from the first half into the second, "despite market volatility", which has had a "limited economic impact" on the firm. L&G said it expects to deliver annual operating profit growth in line with the 8% seen in the first half.

It said recent "extraordinary" interest rate hikes have been challenging for its pension fund clients and counterparties of its Investment Management liability-driven investment business. However, recent purchases of long-dated gilts by the Bank of England have helped to alleviate the pressure.

Its annuity portfolio continues to perform well, and "has not experienced any difficulty in meeting collateral calls and we have not been forced sellers of gilts or bonds", it said.

L&G estimates a solvency coverage ratio between 235% to 240% as at September 30.

In the FTSE 250, Greggs gained 6.0%.

The pastry chain said total sales were up 15% for the 13 weeks to October 1, and backed its full-year expectations.

It continues to expect around 150 net shop openings in 2022, and left its cost inflation outlook unchanged for the year at around 9%.

"As expected, year-on-year growth moderated in August given the particularly strong 'staycation' effect seen in 2021, however, momentum returned in September. We closed our shops on September 19 for the funeral of Her Majesty The Queen and this impacted reported LFL sales growth for the third quarter by around one percentage point," the food-to-go seller noted.

It acknowledged "considerable" economic uncertainty but expects full-year results to be in line with previous expectations.

Royal Mail rose 3.1%, as its name change to International Distributions Services takes effect. It was first announced back in July.

Wizz Air rose 2.8%, after sharing significant annual growth in September. The budget airline said passengers in the month were up 52% year-on-year to 4.5 million, as capacity rose 37% to 5.3 million.

Ryanair also put in a good performance in the month, with guests rising 49% year-on-year to 15.9 million, and load factor improving to 94% from 81% a year prior. Its shares were up 2.5% in Dublin.

On AIM, N4 Pharma was 12% higher as it reported the successful in vitro testing of Nuvec, its novel delivery system for cancer treatments and vaccines.

Poolbeg Pharma rose 6.0%. The pharmaceutical firm said the US Patent & Trademarks Office has indicated that its patent application "that is directed to the use of POLB 001 and its homologues for the treatment of hypercytokinemia" is allowable.

It expects the formal patent grant in due course, and has filed a continuing application to protect additional claims around this indication.

The euro stood at USD0.9871, up against USD0.9834 at the same time on Monday.

Against the yen, the dollar was trading at JPY144.67, higher compared to JPY144.35 late Monday.

Brent oil was quoted at USD89.38 a barrel at the London equities open Tuesday, up from USD88.30 late Monday.

Gold was quoted at USD1,706.10 an ounce Tuesday, higher against USD1,690.38 at the close on Monday.

Stocks in the Asia Pacific region were stronger on Tuesday. The Nikkei 225 in Tokyo closed up 3.0%, while the S&P/ASX 200 in Sydney ended up 3.8%, after an unexpectedly dovish move from its central bank.

"Australia injected some hope into the region, as its central bank lifted interest rates by just 0.25%, rather less than expected, and prompting wider hopes that other monetary authorities might also consider such a wait and see approach," said ii's Richard Hunter.

In China, financial markets were closed as National Day Golden Week continues.

Still to come in the day's economic calendar, there's EU producer inflation at 1000 BST, and comments from US Federal Reserve officials later in the day.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.